Visit our Christmas Gift Finder
Click & Collect from 2 Hours*
Free Delivery to UK Shops
Free UK Standard Delivery On all orders £20 and over Free Delivery to UK Shops Local shops and expert booksellers nationwide Free Click & Collect to UK shops From 2 hours of your order*
Advances in Biology and Therapy of Multiple Myeloma: Volume 2: Translational and Clinical Research (Paperback)
  • Advances in Biology and Therapy of Multiple Myeloma: Volume 2: Translational and Clinical Research (Paperback)
zoom

Advances in Biology and Therapy of Multiple Myeloma: Volume 2: Translational and Clinical Research (Paperback)

(editor), (editor)
£149.99
Paperback 290 Pages / Published: 28/01/2015
  • We can order this

Usually dispatched within 3 weeks

  • This item has been added to your basket
Despite the advances in conventional, novel agent and high dose chemotherapy multiple myeloma (MM) remains incurable. In order to overcome resistance to current therapies and improve patient outcome, novel biologically-based treatment approaches are being developed. Current translational research in MM focusing on the development of molecularly-based combination therapies has great promise to achieve high frequency and durable responses in the majority of patients. Two major advances are making this goal possible. First, recent advances in genomics and proteomics in MM have allowed for increased understanding of disease pathogenesis, identified novel therapeutic targets, allowed for molecular classification, and provided the scientific rationale for combining targeted therapies to increase tumor cell cytotoxicity and abrogate drug resistance. Second, there is now an increased understanding of how adhesion of MM cells in bone marrow (BM) further impacts gene expression in MM cells, as well as in BM stromal cells (BMSCs). As a result of these advances in oncogenomics on the one hand and increased understanding of the role of the BM in the pathogenesis of MM on the other, a new treatment paradigm targeting the tumor cell and its BM microenvironment to overcome drug resistance and improve patient outcome has now been developed. Thalidomide, lenalidomide, and Bortezomib are three agents which target the tumor cell in its microenvironment in both laboratory and animal models and which have rapidly translated from the bench to the bedside. Ongoing efforts are using oncogenomics and cell signaling studies to identify next generation of therapies in MM on the one hand, and to inform the design of combination trials on the other. This new paradigm for overcoming drug resistance and improving patient outcome in MM has great promise not only to change the natural history of MM, but also to serve as a model for targeted therapeutics directed to improve outcome of patients with MM.

Publisher: Springer-Verlag New York Inc.
ISBN: 9781489989147
Number of pages: 290
Weight: 4569 g
Dimensions: 235 x 155 x 16 mm
Edition: 2013 ed.

You may also be interested in...

The Cancer Survivor's Companion
Added to basket
C List
Added to basket
£10.99
Paperback
Radical Remission
Added to basket
Physics for Clinical Oncology
Added to basket
Cancer Care
Added to basket
£7.99
Paperback
Added Time
Added to basket
£6.99
Paperback
The Biology of Cancer
Added to basket
Oxford Handbook of Oncology
Added to basket
Medicine Hands
Added to basket
£29.99
Paperback
Cancer Chemotherapy
Added to basket
The Chemotherapy Survival Guide
Added to basket

Please sign in to write a review

Your review has been submitted successfully.